Literature DB >> 26657867

Past Decline Versus Current eGFR and Subsequent ESRD Risk.

Csaba P Kovesdy1, Josef Coresh2, Shoshana H Ballew3, Mark Woodward4, Adeera Levin5, David M J Naimark6, Joseph Nally7, Dietrich Rothenbacher8, Benedicte Stengel9, Kunitoshi Iseki10, Kunihiro Matsushita3, Andrew S Levey.   

Abstract

eGFR is a robust predictor of ESRD risk. However, the prognostic information gained from the past trajectory (slope) beyond that of the current eGFR is unclear. We examined 22 cohorts to determine the association of past slopes and current eGFR level with subsequent ESRD. We modeled hazard ratios as a spline function of slopes, adjusting for demographic variables, eGFR, and comorbidities. We used random effects meta-analyses to combine results across studies stratified by cohort type. We calculated the absolute risk of ESRD at 5 years after the last eGFR using the weighted average baseline risk. Overall, 1,080,223 participants experienced 5163 ESRD events during a mean follow-up of 2.0 years. In CKD cohorts, a slope of -6 versus 0 ml/min per 1.73 m(2) per year over the previous 3 years (a decline of 18 ml/min per 1.73 m(2) versus no decline) associated with an adjusted hazard ratio of ESRD of 2.28 (95% confidence interval, 1.88 to 2.76). In contrast, a current eGFR of 30 versus 50 ml/min per 1.73 m(2) (a difference of 20 ml/min per 1.73 m(2)) associated with an adjusted hazard ratio of 19.9 (95% confidence interval, 13.6 to 29.1). Past decline contributed more to the absolute risk of ESRD at lower than higher levels of current eGFR. In conclusion, during a follow-up of 2 years, current eGFR associates more strongly with future ESRD risk than the magnitude of past eGFR decline, but both contribute substantially to the risk of ESRD, especially at eGFR<30 ml/min per 1.73 m(2).
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  end-stage renal disease; epidemiology and outcomes; glomerular filtration rate; progression of chronic renal failure

Mesh:

Year:  2015        PMID: 26657867      PMCID: PMC4978053          DOI: 10.1681/ASN.2015060687

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  31 in total

1.  Longitudinal progression trajectory of GFR among patients with CKD.

Authors:  Liang Li; Brad C Astor; Julia Lewis; Bo Hu; Lawrence J Appel; Michael S Lipkowitz; Robert D Toto; Xuelei Wang; Jackson T Wright; Tom H Greene
Journal:  Am J Kidney Dis       Date:  2012-01-26       Impact factor: 8.860

2.  Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.

Authors:  Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

3.  Genetic basis of nondiabetic end-stage renal disease.

Authors:  Barry I Freedman; Rulan S Parekh; W H Linda Kao
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

4.  A simple method of estimating progression of chronic renal failure.

Authors:  W E Mitch; M Walser; G A Buffington; J Lemann
Journal:  Lancet       Date:  1976-12-18       Impact factor: 79.321

5.  GFR decline and mortality risk among patients with chronic kidney disease.

Authors:  Robert M Perkins; Ion D Bucaloiu; H Lester Kirchner; Nasrin Ashouian; James E Hartle; Taher Yahya
Journal:  Clin J Am Soc Nephrol       Date:  2011-06-16       Impact factor: 8.237

6.  Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.

Authors:  Marije van der Velde; Kunihiro Matsushita; Josef Coresh; Brad C Astor; Mark Woodward; Andrew Levey; Paul de Jong; Ron T Gansevoort; Marije van der Velde; Kunihiro Matsushita; Josef Coresh; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Ron T Gansevoort; Andrew Levey; Meguid El-Nahas; Kai-Uwe Eckardt; Bertram L Kasiske; Toshiharu Ninomiya; John Chalmers; Stephen Macmahon; Marcello Tonelli; Brenda Hemmelgarn; Frank Sacks; Gary Curhan; Allan J Collins; Suying Li; Shu-Cheng Chen; K P Hawaii Cohort; Brian J Lee; Areef Ishani; James Neaton; Ken Svendsen; Johannes F E Mann; Salim Yusuf; Koon K Teo; Peggy Gao; Robert G Nelson; William C Knowler; Henk J Bilo; Hanneke Joosten; Nanno Kleefstra; K H Groenier; Priscilla Auguste; Kasper Veldhuis; Yaping Wang; Laura Camarata; Beverly Thomas; Tom Manley
Journal:  Kidney Int       Date:  2011-02-09       Impact factor: 10.612

7.  Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system.

Authors:  Stephen F Derose; Mark P Rutkowski; Peter W Crooks; Jiaxiao M Shi; Jean Q Wang; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Nathan W Levin; Steven J Jacobsen
Journal:  Am J Kidney Dis       Date:  2013-03-15       Impact factor: 8.860

8.  Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan.

Authors:  Ting-Yuan David Cheng; Sung-Feng Wen; Brad C Astor; Xuguang Grant Tao; Jonathan M Samet; Chi Pang Wen
Journal:  Am J Kidney Dis       Date:  2008-08-15       Impact factor: 8.860

Review 9.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.

Authors:  Bakhtawar K Mahmoodi; Kunihiro Matsushita; Mark Woodward; Peter J Blankestijn; Massimo Cirillo; Takayoshi Ohkubo; Peter Rossing; Mark J Sarnak; Bénédicte Stengel; Kazumasa Yamagishi; Kentaro Yamashita; Luxia Zhang; Josef Coresh; Paul E de Jong; Brad C Astor
Journal:  Lancet       Date:  2012-09-24       Impact factor: 79.321

10.  Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate.

Authors:  Kunihiro Matsushita; Bakhtawar K Mahmoodi; Mark Woodward; Jonathan R Emberson; Tazeen H Jafar; Sun Ha Jee; Kevan R Polkinghorne; Anoop Shankar; David H Smith; Marcello Tonelli; David G Warnock; Chi-Pang Wen; Josef Coresh; Ron T Gansevoort; Brenda R Hemmelgarn; Andrew S Levey
Journal:  JAMA       Date:  2012-05-09       Impact factor: 56.272

View more
  34 in total

1.  Predictors of Initiation for Predialysis Arteriovenous Fistula.

Authors:  Alian Al-Balas; Timmy Lee; Carlton J Young; Jill Barker-Finkel; Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-14       Impact factor: 8.237

2.  Impact of visceral fat area in patients with chronic kidney disease.

Authors:  Shun Manabe; Hiroshi Kataoka; Toshio Mochizuki; Kazuhiro Iwadoh; Yusuke Ushio; Keiko Kawachi; Kentaro Watanabe; Saki Watanabe; Taro Akihisa; Shiho Makabe; Masayo Sato; Naomi Iwasa; Rie Yoshida; Yukako Sawara; Norio Hanafusa; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2021-02-17       Impact factor: 2.801

3.  Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.

Authors:  Eiichiro Kanda; Naoki Kashihara; Kunihiro Matsushita; Tomoko Usui; Hirokazu Okada; Kunitoshi Iseki; Kenichi Mikami; Tetsuhiro Tanaka; Takashi Wada; Hirotaka Watada; Kohjiro Ueki; Masaomi Nangaku
Journal:  Clin Exp Nephrol       Date:  2018-12       Impact factor: 2.801

4.  End-Stage Renal Disease Outcomes among the Kaiser Permanente Southern California Creatinine Safety Program (Creatinine SureNet): Opportunities to Reflect and Improve.

Authors:  John J Sim; Michael Batech; Kim N Danforth; Mark P Rutkowski; Steven J Jacobsen; Michael H Kanter
Journal:  Perm J       Date:  2017

5.  Mortality risk among screened subjects of the specific health check and guidance program in Japan 2008-2012.

Authors:  Kunitoshi Iseki; Koichi Asahi; Kunihiro Yamagata; Shouichi Fujimoto; Kazuhiko Tsuruya; Ichiei Narita; Tsuneo Konta; Masato Kasahara; Yugo Shibagaki; Hisako Yoshida; Toshiki Moriyama; Masahide Kondo; Chiho Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2017-03-03       Impact factor: 2.801

6.  Constipation and Incident CKD.

Authors:  Keiichi Sumida; Miklos Z Molnar; Praveen K Potukuchi; Fridtjof Thomas; Jun Ling Lu; Kunihiro Matsushita; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  J Am Soc Nephrol       Date:  2016-11-10       Impact factor: 10.121

7.  Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.

Authors:  Csaba P Kovesdy; Kunihiro Matsushita; Yingying Sang; Nigel J Brunskill; Juan J Carrero; Gabriel Chodick; Takeshi Hasegawa; Hiddo L Heerspink; Atsushi Hirayama; Gijs W D Landman; Adeera Levin; Dorothea Nitsch; David C Wheeler; Josef Coresh; Stein I Hallan; Varda Shalev; Morgan E Grams
Journal:  Eur Heart J       Date:  2018-05-01       Impact factor: 29.983

8.  Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals with CKD.

Authors:  Paula F Orlandi; Dawei Xie; Wei Yang; Jordana B Cohen; Rajat Deo; Ana C Ricardo; Sarah Schrauben; Xue Wang; L Lee Hamm; Jiang He; James H Sondheimer; Krishna Kallem; Raymond Townsend; Dominic Raj; Afshin Parsa; Amanda H Anderson; Harold I Feldman
Journal:  J Am Soc Nephrol       Date:  2020-10-06       Impact factor: 10.121

Review 9.  Trajectories of kidney function in diabetes: a clinicopathological update.

Authors:  Megumi Oshima; Miho Shimizu; Masayuki Yamanouchi; Tadashi Toyama; Akinori Hara; Kengo Furuichi; Takashi Wada
Journal:  Nat Rev Nephrol       Date:  2021-08-06       Impact factor: 28.314

10.  Dipstick proteinuria and all-cause mortality among the general population.

Authors:  Kunitoshi Iseki; Tsuneo Konta; Koichi Asahi; Kunihiro Yamagata; Shouichi Fujimoto; Kazuhiko Tsuruya; Ichiei Narita; Masato Kasahara; Yugo Shibagaki; Toshiki Moriyama; Masahide Kondo; Chiho Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2018-06-05       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.